For example, in a study by Hegi et al., pseudoprogression was observed in 41% of patients receiving chemotherapy with unmethylated MGMT promoter, in contrast to 91% in patients with hypermethylation, highlighting the importance of MGMT methylation in therapeutic monitoring of GBM patients [65]. Here, MGMT is linked to glioblastoma.